Amphotericin B liposome:
Spectrum:
Absorption: IV administration results in complete bioavailability.
Distribution: Extensively distributed to body tissues and fluids. Poor penetration into CSF.
Metabolism/Excretion: Elimination is very prolonged. Detectable in urine up to 7 wk after discontinuation.
Half-life: Biphasicinitial phase, 2448 hr; terminal phase, 15 days. Lipid complex: 174 hr. Liposomal: 100153 hr.
Contraindicated in:
Use Cautiously in:
CV: chest pain, hypotension, edema, hypertension, tachycardia.
Derm: pruritus, rashes.
F and E: hyperglycemia, hypocalcemia, hypokalemia, hypomagnesemia.
GI: ↑ liver enzymes, diarrhea, hyperbilirubinemia, nausea, vomiting, abdominal pain.
GU: nephrotoxicity, hematuria.
Hemat: anemia, leukopenia, thrombocytopenia.
Local: phlebitis.
MS: arthralgia, myalgia.
Neuro: anxiety, confusion, headache, insomnia.
Resp: dyspnea, hypoxia, wheezing.
Misc: chills, fever, acute infusion reactions, HYPERSENSITIVITY REACTIONS.
Drug-Drug:
Amphotericin Deoxycholate
Amphotericin B Lipid Complex (Abelcet)
Amphotericin B Liposome (AmBisome)
(Generic available)
Amphotericin Deoxycholate
Amphotericin B Lipid Complex
Amphotericin B Liposome
Amphotericin B Deoxycholate
IV Administration:
Amphotericin B Lipid Complex
IV Administration:
Amphotericin B Liposome
IV Administration:
NDC Code*